Novo Nordisk's Wegovy Pill Just Hit 3 Million Prescriptions. Is Wall Street Missing Something With This Beaten-Down Stock?

Novo Nordisk's Wegovy pill has quickly reached 3 million prescriptions, signaling strong early demand and a potential market-share opening against Eli Lilly in GLP-1 weight-loss drugs. The company is also highlighted as relatively cheap at a 10x P/E versus Lilly's 40x, with a 4.1% dividend yield, though 2026 is expected to be a transition year due to U.S. price cuts and generic competition in India. The article frames Novo Nordisk as a value-and-income opportunity despite near-term headwinds and intensifying competition.

Analysis

The market is still pricing NVO as if the GLP-1 story is a one-product, one-country margin reset, but the more important shift is channel mix: moving from injectable to oral should expand the addressable pool faster than headline pricing pressure compresses it. A pill lowers the behavioral barrier enough that persistence and refill dynamics can improve even if efficacy is slightly below the best injectable, which matters more for revenue than trial purity. That creates a second-order winner-takes-share dynamic in primary care and employer channels, where convenience often beats marginal efficacy.

The real strategic risk for Lilly is not the existing injectable franchise but whether it can defend the oral conversion funnel without sacrificing its premium efficacy brand. If NVO’s pill becomes the default “starter” GLP-1, Lilly may be forced to discount more aggressively or accept slower share gains in the least sticky segment of the market. That would pressure category economics for everyone, including compounding/pharmacy intermediaries and payers that have been benefiting from fragmented demand and high list-price spreads.

The bearish case on NVO is near-term earnings optics, not franchise durability. 2026 looks like a reset year because lower net pricing and ex-U.S. generic noise can mask the much larger effect of volume normalization; that sets up a classic multiple-recovery setup if prescription momentum holds for 2-3 quarters. The contrarian point is that a 10x earnings multiple plus a 4%+ dividend implies the market is already discounting a permanent share loss, which is hard to justify if oral adoption scales faster than the street expects.

Catalyst-wise, watch prescription trajectory and payer access over the next 60-120 days: if the pill sustains acceleration after the initial launch burst, the market will have to re-rate the stock before 2026 guidance becomes visible. The key reversal risk is that oral adoption stalls once early enthusiasts are exhausted, or that Lilly uses broader formulary leverage to blunt access. In that scenario, NVO remains a value trap; if not, it’s a mispriced turnaround with defensive income characteristics.

Key Decisions for Investors

• Go long NVO vs long-term underweight in LLY: initiate a 3-6 month pair trade long NVO / short LLY sized for valuation mean reversion, with stop-loss if NVO prescription growth decelerates for two consecutive monthly prints.
• Buy NVO on any post-earnings weakness below 11x forward earnings: risk/reward favors accumulation because the dividend cushions downside while oral GLP-1 adoption can re-rate the multiple over 2-4 quarters.
• Use NVO call spreads for a catalyst window: buy 6-9 month upside call spreads to express a rebound thesis with limited premium outlay, targeting a re-rating toward 13-14x if pill momentum persists.
• Avoid chasing LLY into strength: trim/hedge LLY exposure on the thesis that the oral segment is the next battleground and current multiple leaves little room for margin defense missteps.
• If you need sector exposure, prefer NVO over smaller GLP-1 entrants: the combination of distribution scale, label trust, and capital returns gives NVO better downside support than non-franchise challengers.